Technical420 Site Search

MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) (“MediPharm Labs” or the “Company”) a global leader in specialized, research-driven pharmaceutical-quality cannabis extraction, distillation and derivative products, today announced a further expansion of its innovative, pharma-quality family of branded products with the retail introduction of CBD 100, THC 30 and…

During the last year, the cannabis industry has recorded impressive growth as new markets open across the globe.  The opening of new markets has led to an increase in the number of export agreements, and this has greatly benefitted Canadian cannabis companies. One of the most attractive aspects of this…

During the last year, we have noticed a substantial increase in demand for cannabis concentrates and this comes after Canada legalized cannabis derivative products in late 2019. The change in the types of products that are available is referred to as Canada’s cannabis 2.0 market and we are favorable on…

MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE:MLZ) a global leader in specialized, research-driven cannabis extraction, distillation and derivative products, is pleased to announce MediPharm Labs has entered into a supply agreement with the Société Quebecois Du Cannabis (“SQDC”). MediPharm Labs will supply the growing medical and wellness market in…

MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF), a global leader in specialized, research-driven cannabis extraction, distillation and derivative products, is pleased to announce its wholly owned subsidiary, MediPharm Labs Australia Pty Ltd (“MediPharm Labs Australia”), has entered into a new GMP white-label supply and contract manufacturing agreement with Cannim Australia…

MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE:MLZ) (“MediPharm Labs” or the “Company”) a global leader in specialized, research-driven pharmaceutical-quality cannabis extraction, distillation and derivative products, is pleased to announce the closing of its previously announced “bought deal” offering of units of the Company (the “Units”) for total gross proceeds…

MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE:MLZ) (“MediPharm Labs” or the “Company”) a global leader in specialized, research-driven pharmaceutical-quality cannabis extraction, distillation and derivative products, is pleased to announce that it has entered into an agreement with Cantor Fitzgerald Canada Corp., as lead underwriter and sole bookrunner on behalf…

Last year, we highlighted MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) as one of the most misunderstood and undervalued cannabis companies. Following a series of transformational announcements, we remain bullish on the business and believe that our readers need to be aware of how the story has advanced…

MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) (“MediPharm Labs” or the “Company”), a global leader in specialized, research-driven cannabis extraction, distillation and derivative products, announced it has received a Cannabis Drug Licence (“CDL licence”) from Health Canada. The CDL licence is a critical licence required in the qualification…

2021 has been a banner year for the cannabis sector and we have not even completed two months of the year. So far this year, one of the most significant developments for the cannabis sector was Jazz Pharmaceuticals’ (JAZZ: Nasdaq) acquisition of GW Pharmaceuticals (GWPH: Nasdaq) for more than $7…